Key Highlights: Implications: Wegovy’s new MASH indication turns semaglutide into a dual liver–weight disease asset in India, opening a large, under-treated fatty liver market (about two i...
Key Highlights: Implications: Qdenga’s approval as India’s first dengue vaccine creates a new prevention market in a country where reported cases have risen about 11‑fold in two decad...
Key Highlights: Implications: Poviztra’s new MASH label lets Emcure plug innovator semaglutide directly into India’s emerging fatty liver treatment market, riding on ESSENCE data (63% stea...
Key Highlights: Implications: RPG Life Sciences is launching India’s first fixed-dose Naproxen + Esomeprazole tablet, Naprosyn ES, to enable safer long-term NSAID use by adding gastroprote...
Key Highlights: Implications: The slump sale of Gennova’s small mRNA unit to Immunoscript for ₹139.5 crore effectively exits Emcure from a non-core, low-contribution bu...
Key Highlights: Implications: By reducing injections from 365 to 52 per year at near price parity, and potentially 20–25% lower annual treatment costs versus some analogue basals,&nbs...
Key Highlights: Implications: Mankind Pharma’s AI-led drug discovery partnership with Denovo Sciences strengthens its innovation agenda and adds another serious player to India’s eme...
Latest Developments in Digital Therapeutics The rapid convergence of healthcare and technology is reshaping how diseases are managed and treated. Among the most promising innovations in this spa...
Key Highlights: Implications: MSN joins the generics stampede, slashing premium GLP-1 prices and handing endocrinologists budget-friendly options for mass diabetes management.&n...
